Cargando…
No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.
One hundred and eighty seven patients (155 males, 32 females) with histologically proven and previously untreated head and neck cancer were entered in the study. A total of 222 cycles of therapy were analyzed (cisplatin 100 mg m-2 on day 1 and 5-day continuous intravenous infusion of 5-FU 550-1069 m...
Autores principales: | Fleming, R. A., Milano, G. A., Etienne, M. C., Renée, N., Thyss, A., Schneider, M., Demard, F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977433/ https://www.ncbi.nlm.nih.gov/pubmed/1419604 |
Ejemplares similares
-
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.
por: Santini, J., et al.
Publicado: (1989) -
5-FU toxicity and nutritional deficiencies.
por: Stenram, U.
Publicado: (1993) -
5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010) -
Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines
por: Suetsugu, Tomonari, et al.
Publicado: (2021) -
Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
por: Saunders, M P, et al.
Publicado: (2004)